Gilead Sciences, Inc.’s first-in-class immunotherapy candidate, magrolimab, has been hit with a partial clinical hold from the US Food and Drug Administration in acute myeloid leukemia (AML), less than a month after it discontinued a pivotal trial of the drug in myelodysplastic syndromes (MDS).
Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML
Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.

More from Clinical Trials
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.